#China #Hangzhou #medical technology #Zylox-Tonbridge #Optimed

Zylox-Tonbridge's Impressive Performance in First-Half 2026

Zylox-Tonbridge Medical Technology Co., Ltd. has announced its interim results for the six months that ended on June 30, 2026, showcasing a remarkable growth trajectory. The company's revenue jumped 31.1% year-on-year, reaching RMB 632 million, while net profit surged by 47.8% to RMB 179 million. These positive figures reflect an increase in both gross profit margin and net profit margin, which stood at 73.4% and 28.3%, respectively, indicating stronger overall profitability.

International Revenue Surge

A standout feature of Zylox-Tonbridge's results is the extraordinary growth in international revenue, which surged by 349.3% to RMB 70.64 million. This segment now accounts for 11.2% of the company’s total revenue, indicating a significant expansion in its global footprint.

The acquisition of a 60% stake in the German medical technology company, optimed, during April 2026 has been instrumental in this growth. By integrating optimed's market access and commercial resources, Zylox-Tonbridge is poised to enhance its research, development, manufacturing, and commercialization capabilities within Europe.

Through this strategic move, Zylox-Tonbridge has successfully commercialized its products in 70 countries and regions, while its distribution network now spans over 135 territories. Notably, the EMEA region constituted a massive 76% of the international revenue, highlighting its importance in the company's global strategy.

The recent merger of the sales and marketing teams from both companies has fostered a unified global organization, bolstering collaboration in supply-chain management, automation of stent-manufacturing processes, and logistics. This operational synergy has led to the company reaching over 80% of group purchasing organizations in Germany and France.

Channel Expansion and Local Market Penetration

Zylox-Tonbridge accelerated channel integration across Europe and enhanced direct sales operations, securing its first direct sales orders in Germany and France by July 2026. The company has also been diligent in strengthening its channel networks in Latin America and Asia-Pacific, achieving clinical adoption of key products like the Zynlastic™ Peripheral Venous Stent System and the ZYLOX Unicorn™ Vascular Closure System in new markets like Brazil and South Korea.

Focus on Innovation and Portfolio Expansion

Zylox-Tonbridge's commitment to innovation is evident in its expanded product portfolio. In the first half of 2026 alone, the company received approval from NMPA for 11 new products in China, enhancing its range of neurovascular and peripheral vascular interventional medical devices.

The company’s existing products, notably the Kylin™ Flow Diverter and SilverSnake™ Intracranial Intermediate Catheter Series, have shown substantial revenue growth. Furthermore, the newly approved Falco™ Embolization Assist Stent has started contributing to the company's revenue streams. Additionally, developments in the Intracranial OCT System and the Self-expandable Aneurysm Embolization Device are in progress, with ten products currently accepted into the NMPA's Special Review Procedure for innovative medical devices.

Looking Ahead

The outlook for Zylox-Tonbridge remains optimistic as the company heads into the latter half of 2026. With a robust innovation pipeline and a focus on expanding its global reach, Zylox-Tonbridge aims to enhance its collaboration across research, development, and commercialization efforts. The commitment to delivering high-quality and affordable medical solutions to physicians and patients worldwide is evident as the company continues to strengthen its market position and reputation.

In summary, Zylox-Tonbridge Medical Technology Co., Ltd. has made remarkable strides in the first half of 2026, showcasing a strong performance marked by significant revenue growth across both domestic and international markets. With a focus on continuous improvement and innovation, the company is well-positioned for future success.